ichrogene
Ichrogene is a leading global genomic analysis company that creates value through precise health management using big genomic data. They develop and provide advanced genetic analysis services, including AI-based disease risk prediction, personalized genetic information analysis, and comprehensive genomic platforms. Their mission is to expand the utilization of genomic information for health and disease management, contributing to improved quality of life and healthcare cost reduction.
Industries
Nr. of Employees
small (1-50)
ichrogene
Gwangju, North District, Chueam-ro 249, 211ho, Techno Park
Products
Cloud genomic analysis platform
Integrated genomic analysis product combining cloud compute, GPU-accelerated pipelines, automated preprocessing/variant discovery, quality control and reporting via a web UI for research and clinical workflows.
Cloud genomic analysis platform
Integrated genomic analysis product combining cloud compute, GPU-accelerated pipelines, automated preprocessing/variant discovery, quality control and reporting via a web UI for research and clinical workflows.
Services
Precision genomic risk assessment focused on diabetes risk, complications and pharmacogenomic stratification using PRS/AI models and population genomic data; delivered through clinician-mediated workflows with laboratory analysis and report delivery via web/app.
Clinic-channel genetic testing service offering interpretation across a broad set of conditions (stated ~1,000 items) using large reference datasets and analytic models; includes clinician consultation pathway and sample collection logistics.
Provisioning and operation of a cloud-hosted genomic analysis platform that integrates high-performance pipelines, web UI and marketplace distribution for preprocessing, variant discovery, QC and reporting; supports on-demand GPU compute.
Integration of genomic data with electronic health records and lifelog/wearable data to support personalized health management, digital-twin applications, and real-world data collection via mobile and web platforms.
Design and operational support for population-scale genomic and AI health programs, including participant recruitment, sample logistics, data generation, platform-based participant management and integration with local hospitals or public health authorities.
Licensing or transfer of analytic methods for genomic high-risk group identification and related analytic techniques to external institutions and partners.
Precision genomic risk assessment focused on diabetes risk, complications and pharmacogenomic stratification using PRS/AI models and population genomic data; delivered through clinician-mediated workflows with laboratory analysis and report delivery via web/app.
Clinic-channel genetic testing service offering interpretation across a broad set of conditions (stated ~1,000 items) using large reference datasets and analytic models; includes clinician consultation pathway and sample collection logistics.
Provisioning and operation of a cloud-hosted genomic analysis platform that integrates high-performance pipelines, web UI and marketplace distribution for preprocessing, variant discovery, QC and reporting; supports on-demand GPU compute.
Integration of genomic data with electronic health records and lifelog/wearable data to support personalized health management, digital-twin applications, and real-world data collection via mobile and web platforms.
Design and operational support for population-scale genomic and AI health programs, including participant recruitment, sample logistics, data generation, platform-based participant management and integration with local hospitals or public health authorities.
Licensing or transfer of analytic methods for genomic high-risk group identification and related analytic techniques to external institutions and partners.
Expertise Areas
- Population-scale genomic data curation
- Whole-genome and whole-exome analysis pipelines
- Polygenic risk scoring and AI-driven disease risk prediction
- Genotyping array design and genotype imputation
Key Technologies
- Whole-genome sequencing (WGS) analysis
- Whole-exome sequencing (WES) analysis
- Genotyping arrays and imputation
- GPU-accelerated compute for genomics
News & Updates
Ichrogene's CEO announced successful market entry into Thailand, collaborating with local hospitals and expanding genetic testing solutions in Southeast Asia.
The company showcased its brand and services at the 2023 Bio Convention in Boston, highlighting its global presence.
Ichrogene signed an MOU with Thonburi Hospital to launch genetic testing services for chronic diseases in Bangkok.
Naver invested in Ichrogene, supporting its expansion into Southeast Asia, especially Thailand, with genetic testing solutions.
Ichrogene announced its successful funding round, led by strategic investors including Naver and others, emphasizing its leadership in AI genetic analysis.
The company is actively involved in digital healthcare projects, utilizing big data and AI to predict and manage diseases.
Ichrogene's CEO announced successful market entry into Thailand, collaborating with local hospitals and expanding genetic testing solutions in Southeast Asia.
The company showcased its brand and services at the 2023 Bio Convention in Boston, highlighting its global presence.
Ichrogene signed an MOU with Thonburi Hospital to launch genetic testing services for chronic diseases in Bangkok.
Naver invested in Ichrogene, supporting its expansion into Southeast Asia, especially Thailand, with genetic testing solutions.
Ichrogene announced its successful funding round, led by strategic investors including Naver and others, emphasizing its leadership in AI genetic analysis.
The company is actively involved in digital healthcare projects, utilizing big data and AI to predict and manage diseases.